http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003017968-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-39 |
| filingDate | 2002-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86883f6f79aee6aec542fddffa6ea534 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c18a07dd0edefe9e7704549cfc2c6ef8 |
| publicationDate | 2003-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003017968-A1 |
| titleOfInvention | Use of isolated domains of type IV collagen to modify cell and tissue interactions |
| abstract | The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 α chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (α1), (α2), (α3), or (α6) chain monomer, or protein constructs having substantially the same structure as the NC1 (α1), (α2), (α3), or (α6) chain monomer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022110842-A1 |
| priorityDate | 1995-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.